# Thor Medical and ARTBIO sign supply agreement for Thorium-228

Thor Medical signed a strategic master supply agreement with ARTBIO for a 5-year supply of Thorium-228, with potential revenues of up to NOK 400 million (USD 38 million). The Thorium-228 will be produced at Thor Medical's planned commercial facility at Herøya Industrial Park in Norway, with an investment decision expected in Q1 2025.

- Type: Contract
- Announced: 2024-10-29
- Where: Herøya Industrial Park, Norway
- Value: $17.0M
- Status: announced
- Products: Thorium-228
- Sectors: [Specialty Chemicals](https://endata.com/sectors/specialty-chemicals.md)

## Companies

- [Thor Medical AS](https://endata.com/companies/70997.md)
- [ARTBIO](https://endata.com/companies/80753.md) (customer)

## Sources

- [live.euronext.com](https://live.euronext.com/en/products/equities/company-news/2024-10-29-thor-medical-and-artbio-sign-strategic-long-term-supply), 2024-10-29: "Securing strategic supply agreements are an important prerequisite for a positive investment decision for our planned commercial production plant."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.